(Q39345249)

11 September 2017

Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model (English)

1 reference

11 September 2017

endometrial carcinoma

1 reference

Yanli Xu

1

1 reference

11 September 2017

Jianqian Tong

2

1 reference

11 September 2017

Zhihong Ai

3

1 reference

11 September 2017

Juan Wang

4

1 reference

11 September 2017

Yincheng Teng

5

1 reference

11 September 2017

21 May 2012

1 reference

Journal of Obstetrics and Gynaecology Research

11 September 2017

1 reference

11 September 2017

38

1 reference

11 September 2017

12

1 reference

11 September 2017

1358-1366

1 reference

Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger

11 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

Progesterone receptors in endometrial cancer invasion and metastasis: development of a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

Systemic therapy in metastatic or recurrent endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

The epidermal growth factor receptor: a new target for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.2012.01881.X

10.1111/J.1447-0756.2012.01881.X

21 January 2018

Identifiers

DOI

1 reference

release_qoo7ukmwtjfxxj3xk2ft2ghjre

11 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qoo7ukmwtjfxxj3xk2ft2ghjre

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference